MX2019010732A - Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. - Google Patents

Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.

Info

Publication number
MX2019010732A
MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A
Authority
MX
Mexico
Prior art keywords
catecholamine
cst
tumors
cushing
bind
Prior art date
Application number
MX2019010732A
Other languages
English (en)
Inventor
G Moraitis Andreas
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2019010732A publication Critical patent/MX2019010732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

Se describen novedosos métodos para tratar tumores, que incluyen tumores neuroendocrinos (NET), tal como un tumor secretor de catecolamina (CST). Los métodos incluyen síndrome de Cushing en un paciente con síndrome de Cushing que tiene un NET, tal como un CST. Los tumores pueden ser tratados con un modulador de receptor de glucocorticoide (GR) (GRM), tal como un antagonista de GR (GRA). Los novedosos tratamientos pueden tratar síndrome de Cushing, pueden reducir la producción de catecolamina por el tumor, pueden reducir el exceso de catecolamina, pueden mejorar los síntomas de exceso de catecolamina y pueden mejorar la eficacia de bloqueo a- o ß-adrenérgico, tratamiento o imagenología con somatostatina o análogo de somatostatina, o terapia de radionúclido de receptor de péptido, en pacientes con un CST. El GRM puede reducir la activación de un GR y pueden unirse a un GR con mayor afinidad que con la que se une a un receptor de progesterona (PR). En modalidades, el fármaco puede unirse solo pobremente a PR y puede no unirse de manera medible a PR.
MX2019010732A 2017-03-09 2018-03-08 Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. MX2019010732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469296P 2017-03-09 2017-03-09
PCT/US2018/021592 WO2018165460A1 (en) 2017-03-09 2018-03-08 Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

Publications (1)

Publication Number Publication Date
MX2019010732A true MX2019010732A (es) 2019-11-01

Family

ID=63446773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010732A MX2019010732A (es) 2017-03-09 2018-03-08 Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.

Country Status (8)

Country Link
US (1) US11045482B2 (es)
EP (1) EP3592358A4 (es)
JP (3) JP7564620B2 (es)
CN (1) CN110475558A (es)
AU (1) AU2018230429B2 (es)
CA (1) CA3053806A1 (es)
MX (1) MX2019010732A (es)
WO (1) WO2018165460A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3122581A1 (en) * 2018-12-20 2020-06-25 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
JP2021079146A (ja) * 2021-02-22 2021-05-27 株式会社三洋物産 遊技機
JP7315071B2 (ja) * 2021-03-03 2023-07-26 株式会社三洋物産 遊技機

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
CA2325169A1 (en) 1999-12-03 2001-06-03 Ndsu Research Foundation Somatostatins and method
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
CA2440605C (en) * 2001-03-23 2012-01-10 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
AU2002359359A1 (en) 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
DK1735308T3 (da) 2004-03-09 2009-01-19 Corcept Therapeutics Inc Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
JP2010527452A (ja) * 2007-05-15 2010-08-12 ウオーターズ・テクノロジーズ・コーポレイシヨン 血漿メタネフリンを検出するための装置および方法
EP2211845B1 (en) 2007-10-17 2017-02-22 Laboratoire HRA Pharma Glucocorticoid receptor antagonists such as mifepristone for treating cushing's syndrome
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
CA2761255C (en) 2009-05-12 2017-05-09 Corcept Therapeutics, Inc. Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene
US10071030B2 (en) * 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP6039587B2 (ja) 2011-03-18 2016-12-07 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP6516743B2 (ja) 2013-11-25 2019-05-22 コーセプト セラピューティクス， インコーポレイテッド オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
US9943526B2 (en) * 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Also Published As

Publication number Publication date
JP7564620B2 (ja) 2024-10-09
WO2018165460A1 (en) 2018-09-13
EP3592358A4 (en) 2020-12-16
JP2020510011A (ja) 2020-04-02
US11045482B2 (en) 2021-06-29
US20180256604A1 (en) 2018-09-13
CN110475558A (zh) 2019-11-19
AU2018230429B2 (en) 2023-06-15
AU2018230429A1 (en) 2019-09-05
CA3053806A1 (en) 2018-09-13
JP2022090003A (ja) 2022-06-16
JP2024074854A (ja) 2024-05-31
EP3592358A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
Sato et al. Increasing intensity of TENS prevents analgesic tolerance in rats
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
WO2016187220A3 (en) Anti-ror1 antibodies
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
SG10201902664RA (en) Combination therapy for treating cancer
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010732A (es) Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.
GB2454118A (en) Hdac inhibitors and hormone targeted drugs for the treatment of cancer
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
PL2288413T3 (pl) Urządzenie terapeutyczne łączące radioterapię z termoterapią
EA201391286A1 (ru) Лечение солидных опухолей
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
ZA202304965B (en) Combination therapy for treating cancer
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
AR082353A1 (es) Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020013601A (es) Receptores de las celulas t especificos de cancer.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy